The Anti-CD38 Monoclonal Antibody TAK-079 Depletes Antibody Secreting Cells from Normal and SLE Patients

被引：0
|
作者：
Wang, Xiaoqian [1 ,2 ]
Dahl, Martin [3 ]
Nguyen, Doan [4 ]
Jenks, Scott [1 ,2 ]
Cashman, Kevin [1 ,2 ]
Lee, F. Eun-Hyung [5 ]
McLean, Lachy [6 ]
Sanz, Ignacio [2 ,7 ]
机构：
[1] Emory Univ, Sch Med, Div Rheumatol, Atlanta, GA USA
[2] Emory Univ, Sch Med, Lowance Ctr Human Immunol, Atlanta, GA USA
[3] Tekada Pharmaceut, San Diego, CA USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] Emory Univ, Sch Med, Med, Atlanta, GA USA
[6] Takeda Global Res & Dev Ctr Inc, San Diego, CA USA
[7] Emory Univ, Sch Med, Rheumatol, Atlanta, GA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1085
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combination of the anti-CD38 monoclonal antibody daratumumab and all-trans retinoic acid.
    Nijhof, Inger S.
    Lokhorst, Henk M.
    van Kessel, Berris
    Doshi, Parul
    Sasser, Kate
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [32] Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
    Benfaremo, Devis
    Gabrielli, Armando
    CELLS, 2020, 9 (01)
  • [33] A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India
    Biswas, Durba
    Basu, Debapriya
    Nag, Arijit
    Kumar, Jeevan
    Datta, Suvro Sankha
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (04) : 728 - 729
  • [34] Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab
    ElMaraashly, Aya Hassan
    Tario, Joseph
    Hillengass, Jens
    Qian, You-Wen
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 (05) : 524 - 532
  • [35] Solid phase antibody screening in the presence of anti-CD38 monoclonal antibodies: a potential alternative to avoid interference
    Perram, J.
    Blayney, B.
    Ackerman, L.
    Beig, A.
    Khoo, L.
    PATHOLOGY, 2020, 52 (04) : 492 - 494
  • [36] Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma
    Lonial, Sagar
    Bowser, Andrew D.
    Chari, Ajai
    Costello, Caitlin
    Krishnan, Amrita
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : 815 - 824
  • [37] Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)
    Moreno, Laura
    Zabaleta, Aintzane
    Alignani, Diego
    Ajona, Daniel
    Lasa, Marta
    Maiso, Patricia
    Jelinek, Tomas
    Segura, Victor
    Delgado, Jose Antonio
    Rodriguez-Otero, Paula
    Prosper, Felipe
    San Miguel, Jesus
    Paiva, Bruno
    BLOOD, 2016, 128 (22)
  • [38] An anti-CD38 antibody drug conjugate for the treatment of diverse hematologic malignancies
    Prudent, James R.
    Marshall, David J.
    Murphy, John
    Malavasi, Fabio
    CANCER RESEARCH, 2015, 75
  • [39] Structural characterization of a potent humanized anti-CD38 antibody in phase I
    Vallee, F.
    Pouzieux, S.
    Rak, A.
    Michoux, F.
    Wetzel, M.
    Deckert, J.
    Kannt, A.
    Blanc, V.
    Mikol, V.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 : C1813 - C1813
  • [40] Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy
    Malavasi, Fabio
    Faini, Angelo Corso
    CLINICAL CANCER RESEARCH, 2019, 25 (10) : 2946 - 2948
12345